Scott R Solomon
Overview
Explore the profile of Scott R Solomon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
3594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hickey C, Zhang M, Allbee-Johnson M, Romee R, Majhail N, Al Malki M, et al.
Transplant Cell Ther
. 2025 Jan;
31(3):174.e1-174.e12.
PMID: 39755256
Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been...
2.
Bashey S, Solomon S, Zhang X, Morris L, Holland H, Bachier L, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1783-1785.
PMID: 39300248
No abstract available.
3.
Solh M, Aubrey M, Zhang X, Bashey A, Freed B, Roark C, et al.
Bone Marrow Transplant
. 2024 Jul;
59(10):1433-1439.
PMID: 39085372
Graft versus tumor relies on tumor-associated antigens (TAAs) that are presented to donor T cells via human leukocyte antigens (HLAs). The HLA evolutionary divergence (HED) between alleles of a single...
4.
Solomon S, Bachier-Rodriguez L, Bashey A, Zhang X, Jackson K, Holland H, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):903.e1-903.e9.
PMID: 38879167
Following conventional graft-versus-host disease (GVHD) prophylaxis, the development of acute and/or chronic GVHD is associated with lower relapse rates. However, the effects of GVHD on relapse and non-relapse mortality following...
5.
Farhadfar N, Rashid N, Chen K, DeVos J, Wang T, Ballen K, et al.
Blood Adv
. 2024 May;
8(18):4963-4976.
PMID: 38776400
Socioeconomic status (SES) and race/ethnicity have been associated with the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HCT). Certain aspects of graft-versus-host disease (GVHD) management, such as the need for...
6.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka A, et al.
Future Oncol
. 2024 Apr;
20(18):1221-1235.
PMID: 38651976
No abstract available.
7.
Solomon S, Aubrey M, Bachier-Rodriguez L, Solh M, Jackson K, Zhang X, et al.
Transplant Cell Ther
. 2024 Apr;
30(6):608.e1-608.e10.
PMID: 38561140
The presence of an HLA-DPB1 nonpermissive mismatch (NPMM) by the TCE-3 model has been associated with improved survival following haploidentical donor transplantation (HIDT) using post-transplantation cyclophosphamide (PTCy). With the development...
8.
Solh M, Bashey A, Zhang X, Holland H, Bachier-Rdriguez L, Morris L, et al.
Transplant Cell Ther
. 2024 Mar;
30(6):607.e1-607.e8.
PMID: 38552844
The development of chronic graft-versus-host disease (GVHD) in 1-year survivors after matched related or unrelated hematopoietic cell transplantation was shown to be associated with higher nonrelapse mortality (NRM) and worse...
9.
Abramson J, Solomon S, Arnason J, Johnston P, Glass B, Bachanova V, et al.
Future Oncol
. 2024 Mar;
20(21):1455-1465.
PMID: 38547003
No abstract available.
10.
Solomon S, Powell B, Koprivnikar J, Lai C, Male H, Michaelis L, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473278
This open-label phase 1 study (clinicaltrials.gov, NCT03555955) assessed CPX-351 pharmacokinetics (PK) and safety in patients with hematologic malignancies with normal or impaired renal function. Patients were enrolled into three cohorts...